RBC Capital Reiterates Outperform on Sarepta Therapeutics, Maintains $181 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital has reiterated its 'Outperform' rating for Sarepta Therapeutics, maintaining a price target of $181. This suggests confidence in the company's future performance.
September 06, 2024 | 12:47 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its 'Outperform' rating for Sarepta Therapeutics, maintaining a price target of $181. This suggests confidence in the company's future performance.
The reiteration of an 'Outperform' rating and a maintained price target of $181 by RBC Capital indicates a positive outlook on Sarepta Therapeutics' stock. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100